Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery

M. K. Sinha, M. L. Collazo-Clavell, Andrew D Rule, D. S. Milliner, W. Nelson, M. G. Sarr, Rajiv Kumar, John C Lieske

Research output: Contribution to journalArticle

157 Citations (Scopus)

Abstract

Roux-en-Y bypass surgery is the most common bariatric procedure currently performed in the United States for medically complicated obesity. Although this leads to a marked and sustained weight loss, we have identified an increasing number of patients with episodes of nephrolithiasis afterwards. We describe a case series of 60 patients seen at Mayo Clinic-Rochester that developed nephrolithiasis after Roux-en-Y gastric bypass (RYGB), including a subset of 31 patients who had undergone metabolic evaluation in the Mayo Stone Clinic. The mean body mass index of the patients before procedure was 57 kg/m2 with a mean decrease of 20 kg/m2 at the time of the stone event, which averaged 2.2 years post-procedure. When analyzed, calcium oxalate stones were found in 19 and mixed calcium oxalate/uric acid stones in two patients. Hyperoxaluria was a prevalent factor even in patients without a prior history of nephrolithiasis, and usually presented more than 6 months after the procedure. Calcium oxalate supersaturation, however, was equally high in patients less than 6 months post-procedure due to lower urine volumes. In a small random sampling of patients undergoing this bypass procedure, hyperoxaluria was rare preoperatively but common 12 months after surgery. We conclude that hyperoxaluria is a potential complicating factor of RYGB surgery manifested as a risk for calcium oxalate stones.

Original languageEnglish (US)
Pages (from-to)100-107
Number of pages8
JournalKidney International
Volume72
Issue number1
DOIs
StatePublished - Jul 2007

Fingerprint

Nephrolithiasis
Gastric Bypass
Calcium Oxalate
Hyperoxaluria
Bariatrics
Uric Acid
Weight Loss
Body Mass Index
Obesity
Urine

Keywords

  • Bariatric surgery
  • Enteric hyperoxaluria
  • Nephrolithiasis
  • Obesity
  • Oxalate
  • Roux-en-Y gastric bypass

ASJC Scopus subject areas

  • Nephrology

Cite this

Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. / Sinha, M. K.; Collazo-Clavell, M. L.; Rule, Andrew D; Milliner, D. S.; Nelson, W.; Sarr, M. G.; Kumar, Rajiv; Lieske, John C.

In: Kidney International, Vol. 72, No. 1, 07.2007, p. 100-107.

Research output: Contribution to journalArticle

Sinha, M. K. ; Collazo-Clavell, M. L. ; Rule, Andrew D ; Milliner, D. S. ; Nelson, W. ; Sarr, M. G. ; Kumar, Rajiv ; Lieske, John C. / Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery. In: Kidney International. 2007 ; Vol. 72, No. 1. pp. 100-107.
@article{640caf579e6e4d40a138a3207141b4f4,
title = "Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery",
abstract = "Roux-en-Y bypass surgery is the most common bariatric procedure currently performed in the United States for medically complicated obesity. Although this leads to a marked and sustained weight loss, we have identified an increasing number of patients with episodes of nephrolithiasis afterwards. We describe a case series of 60 patients seen at Mayo Clinic-Rochester that developed nephrolithiasis after Roux-en-Y gastric bypass (RYGB), including a subset of 31 patients who had undergone metabolic evaluation in the Mayo Stone Clinic. The mean body mass index of the patients before procedure was 57 kg/m2 with a mean decrease of 20 kg/m2 at the time of the stone event, which averaged 2.2 years post-procedure. When analyzed, calcium oxalate stones were found in 19 and mixed calcium oxalate/uric acid stones in two patients. Hyperoxaluria was a prevalent factor even in patients without a prior history of nephrolithiasis, and usually presented more than 6 months after the procedure. Calcium oxalate supersaturation, however, was equally high in patients less than 6 months post-procedure due to lower urine volumes. In a small random sampling of patients undergoing this bypass procedure, hyperoxaluria was rare preoperatively but common 12 months after surgery. We conclude that hyperoxaluria is a potential complicating factor of RYGB surgery manifested as a risk for calcium oxalate stones.",
keywords = "Bariatric surgery, Enteric hyperoxaluria, Nephrolithiasis, Obesity, Oxalate, Roux-en-Y gastric bypass",
author = "Sinha, {M. K.} and Collazo-Clavell, {M. L.} and Rule, {Andrew D} and Milliner, {D. S.} and W. Nelson and Sarr, {M. G.} and Rajiv Kumar and Lieske, {John C}",
year = "2007",
month = "7",
doi = "10.1038/sj.ki.5002194",
language = "English (US)",
volume = "72",
pages = "100--107",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Hyperoxaluric nephrolithiasis is a complication of Roux-en-Y gastric bypass surgery

AU - Sinha, M. K.

AU - Collazo-Clavell, M. L.

AU - Rule, Andrew D

AU - Milliner, D. S.

AU - Nelson, W.

AU - Sarr, M. G.

AU - Kumar, Rajiv

AU - Lieske, John C

PY - 2007/7

Y1 - 2007/7

N2 - Roux-en-Y bypass surgery is the most common bariatric procedure currently performed in the United States for medically complicated obesity. Although this leads to a marked and sustained weight loss, we have identified an increasing number of patients with episodes of nephrolithiasis afterwards. We describe a case series of 60 patients seen at Mayo Clinic-Rochester that developed nephrolithiasis after Roux-en-Y gastric bypass (RYGB), including a subset of 31 patients who had undergone metabolic evaluation in the Mayo Stone Clinic. The mean body mass index of the patients before procedure was 57 kg/m2 with a mean decrease of 20 kg/m2 at the time of the stone event, which averaged 2.2 years post-procedure. When analyzed, calcium oxalate stones were found in 19 and mixed calcium oxalate/uric acid stones in two patients. Hyperoxaluria was a prevalent factor even in patients without a prior history of nephrolithiasis, and usually presented more than 6 months after the procedure. Calcium oxalate supersaturation, however, was equally high in patients less than 6 months post-procedure due to lower urine volumes. In a small random sampling of patients undergoing this bypass procedure, hyperoxaluria was rare preoperatively but common 12 months after surgery. We conclude that hyperoxaluria is a potential complicating factor of RYGB surgery manifested as a risk for calcium oxalate stones.

AB - Roux-en-Y bypass surgery is the most common bariatric procedure currently performed in the United States for medically complicated obesity. Although this leads to a marked and sustained weight loss, we have identified an increasing number of patients with episodes of nephrolithiasis afterwards. We describe a case series of 60 patients seen at Mayo Clinic-Rochester that developed nephrolithiasis after Roux-en-Y gastric bypass (RYGB), including a subset of 31 patients who had undergone metabolic evaluation in the Mayo Stone Clinic. The mean body mass index of the patients before procedure was 57 kg/m2 with a mean decrease of 20 kg/m2 at the time of the stone event, which averaged 2.2 years post-procedure. When analyzed, calcium oxalate stones were found in 19 and mixed calcium oxalate/uric acid stones in two patients. Hyperoxaluria was a prevalent factor even in patients without a prior history of nephrolithiasis, and usually presented more than 6 months after the procedure. Calcium oxalate supersaturation, however, was equally high in patients less than 6 months post-procedure due to lower urine volumes. In a small random sampling of patients undergoing this bypass procedure, hyperoxaluria was rare preoperatively but common 12 months after surgery. We conclude that hyperoxaluria is a potential complicating factor of RYGB surgery manifested as a risk for calcium oxalate stones.

KW - Bariatric surgery

KW - Enteric hyperoxaluria

KW - Nephrolithiasis

KW - Obesity

KW - Oxalate

KW - Roux-en-Y gastric bypass

UR - http://www.scopus.com/inward/record.url?scp=34347350180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34347350180&partnerID=8YFLogxK

U2 - 10.1038/sj.ki.5002194

DO - 10.1038/sj.ki.5002194

M3 - Article

C2 - 17377509

AN - SCOPUS:34347350180

VL - 72

SP - 100

EP - 107

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 1

ER -